A Kaiser Family Foundation study revealed about one in eight adults in the US say they’re taking a GLP-1 drug such as Ozempic ...

The FDA is requesting that manufacturers of three GLP-1 receptor agonists remove information on risk for suicidal ideation ...

This video explores an unusually low-priced Ford Sierra, looking at its condition, history, and why it was listed for so ...

After a period of diversification, Novo Nordisk is returning to its roots by focusing on the 2 billion people with diabetes, ...

BMO analysts say Eli Lilly is well-positioned to maintain its lead in the ballooning weight loss space, predicting “strengthening leadership in obesity and beyond” as portfolios expand and patient ...

The past year was one of turbulence and change at Novo Nordisk, and, while the Danish drugmaker still has its work cut out ...

Friendly” labels on the packaging are becoming more common as a growing number of Americans try obesity drugs like Wegovy and ...

Shed, a leading health and wellness platform focused on accessible, clinician-guided care, today announced the expansion of its GLP-1 weight-loss programs with ...

Federal regulators are telling drugmakers to remove label warnings about potential suicidal thoughts and behaviors from their ...

The U.S. health regulator asked drugmakers on Tuesday to remove warnings about a potential ​risk of suicidal thoughts from widely used GLP-1 weight-loss drugs, including Novo Nordisk's Wegovy and Eli ...

The U.S. health regulator asked drugmakers on Tuesday to remove warnings about a potential risk of suicidal thoughts from ...